MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$156,413K
Net Income
-$722,218K
Net Profit Margin
-461.74%
EPS
-$2.98
Unit: Thousand (K) dollars
Revenue Breakdown
    • Product
    • License And Other Revenues
Revenue Breakdown
    • Product
    • License
    • Collaborative And Other Research...
Revenue Breakdown
    • ORLADEYO
    • Other Income From Contract With ...
    • License

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
156,413 406,555 159,395 163,353
Cost of product sales
5,377 9,522 2,187 2,798
Acquired in-process research and development
697,761 NaN NaN NaN
Research and development
60,319 40,867 44,603 43,386
Selling, general and administrative
94,554 95,781 83,014 87,383
Total operating expenses
858,011 146,170 129,804 133,567
(loss) income from operations
-701,598 260,385 29,591 29,786
Interest income
2,256 2,890 2,238 2,516
Interest expense
19,779 12,257* 19,661 21,582
Foreign currency (losses) gains, net
-225 -125 35 -63
Loss on extinguishment of debt
NaN -6,965* -2,740 -4,171
Other income
NaN 4,089* 2,667 NaN
Other expense, net
-1,462 NaN NaN NaN
Total other expense, net
-19,210 -12,368 -17,461 -23,300
(loss) income before income taxes
-720,808 248,017 12,130 6,486
Income tax expense
1,004 2,172 -769 1,401
Net (loss) income
-721,812 245,845 12,899 5,085
Foreign currency translation adjustment
-62 -1,219 -523 702
Unrealized gain on available for sale investments
-344 117 17 -188
Total other comprehensive (loss) income
-406 -1,102 -506 514
Net comprehensive (loss) income
-722,218 244,743 12,393 5,599
Basic EPS
-2.98 1.16 0.06 0.02
Diluted EPS
-2.98 1.116 0.06 0.02
Basic Average Shares
242,258,000 210,995,000 210,176,000 209,519,000
Diluted Average Shares
242,258,000 219,292,000 219,885,000 219,886,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net comprehensive(loss) income-$722,218K (-297309.05%↓ Y/Y)Net (loss) income-$721,812K (-2255762.50%↓ Y/Y)Total othercomprehensive (loss) income-$406K (loss) income beforeincome taxes-$720,808K (-95193.40%↓ Y/Y)Income tax expense$1,004K (38.29%↑ Y/Y)Unrealized gain onavailable for sale...-$344K (-121.94%↓ Y/Y)Foreign currencytranslation adjustment-$62K (-116.94%↓ Y/Y)Product$151,401K (5.30%↑ Y/Y)License And OtherRevenues$5,012K (loss) income fromoperations-$701,598K (-3405.22%↓ Y/Y)Total other expense,net-$19,210K (6.15%↑ Y/Y)Total revenues$156,413K (7.48%↑ Y/Y)Interest income$2,256K (-25.40%↓ Y/Y)Total operatingexpenses$858,011K (590.24%↑ Y/Y)Interest expense$19,779K (-15.81%↓ Y/Y)Other expense, net-$1,462K Foreign currency(losses) gains, net-$225K (-22600.00%↓ Y/Y)Acquired in-processresearch and development$697,761K Selling, general andadministrative$94,554K (14.65%↑ Y/Y)Research and development$60,319K (61.84%↑ Y/Y)Cost of product sales$5,377K (17.71%↑ Y/Y)

BIOCRYST PHARMACEUTICALS INC (BCRX)

BIOCRYST PHARMACEUTICALS INC (BCRX)